IGF-1 DES
Also known as: DES(1-3) IGF-1
IGF-1 DES is a truncated analogue of insulin-like growth factor 1 missing the first three N-terminal amino acids, used as a research reagent. It is not approved for human use in Australia.
- Category
- Growth Factor
- Reported half-life
- Reported to be short (not well established in humans)
- Common forms
- Lyophilised powder for reconstitution, Solution (research reagent)
- Research status
- Not approved for human use in Australia; used as a laboratory research reagent only. No marketed human therapeutic product.
- Last updated
- 21 June 2026
Claimed effects
The following effects are reported or claimed by users and in early research. They are not established medical facts and many are not supported by large human trials.
- Reported to retain IGF-1 receptor activity with very low binding to IGF binding proteins
- Claimed to act potently but with a short duration
- Users report interest in localised muscle growth and recovery
- Early research indicates strong anabolic effects in vitro
How it is reported to work
IGF-1 DES is reported to be IGF-1 lacking its first three N-terminal amino acids, a change that sharply reduces binding to IGF binding proteins while preserving binding to the IGF-1 receptor. This is proposed to make it potent but relatively short-acting, with effects described as more local. These properties are characterised mainly in cell-culture and laboratory settings, not in controlled human use.
Background
IGF-1 DES (DES(1-3) IGF-1) is a truncated analogue of insulin-like growth factor 1 missing its first three N-terminal amino acids. This change is reported to greatly reduce binding to IGF binding proteins, making the molecule potent but short-acting. It is used as a laboratory research reagent. This page is educational information, not medical advice.
What the research actually shows
IGF-1 DES is characterised mainly in cell-culture and laboratory research, where it is reported to be a strong, short-acting IGF-1 receptor agonist. Controlled human clinical trials using it as an intervention are essentially absent, leaving human benefits and safety unproven.
| Evidence type | Status |
|---|---|
| Cell-culture/laboratory research | Present |
| Human trials | Lacking |
| Australian approval | None |
What people use it for (reported)
Online, people report using IGF-1 DES in attempts to support muscle growth and recovery. These are anecdotal reports, not validated clinical results. Studies suggest potent, short-lived IGF-1 signalling, but reported benefits should not be read as established facts.
Things to be aware of
IGF-1 DES is not approved for human use in Australia. Potent IGF-1 signalling carries theoretical concerns including low blood sugar and cell proliferation, and grey-market product identity and purity cannot be verified by sight.
If you have a health concern, the appropriate step is to talk to a qualified healthcare professional rather than self-experimenting. This article is not an endorsement and does not recommend obtaining or using IGF-1 DES.
Reported positives & side effects
Compiled from research and community reports. These are reported outcomes, not guarantees or medical advice, individual experiences vary widely.
Reported positives
- Reported to be highly potent at the IGF-1 receptor in research settings
- Reported short, localised action of interest for site-specific use
- Reported interest in localised muscle growth and pump
- Reported strong anabolic effects in laboratory models
Common side effects
- Reported hypoglycaemia symptoms such as shakiness, sweating and hunger
- Reported injection-site soreness, redness or swelling
- Reported localised muscle fullness shortly after dosing
- Reported fatigue or light-headedness
Rare / serious side effects
- Reported severe hypoglycaemia that may require urgent carbohydrate intake
- Theoretical concerns around tumour promotion from potent cell-proliferative signalling
- Reported allergic-type reactions to impurities in research-grade product
- Reported localised tissue irregularities with repeated same-site injection
Reported misuse & overdose risks
What has been reported to happen with overuse, excessive dosing, or long-term misuse of IGF-1 DES. Listed so you can make an informed decision, not to suggest any use is safe.
- Because it is highly potent, overuse is reported to provoke sharp hypoglycaemia, with reports of users needing emergency carbohydrate intake.
- Frequent high-dose use is reported to over-activate IGF-1 signalling, raising theoretical cancer-promotion and abnormal-growth concerns.
- Repeated same-site injection is reported to risk localised tissue overgrowth or imbalance.
- Stacking with insulin or other IGF-1 analogues is reported to compound metabolic strain and amplify hypoglycaemia danger.
Reported results timeline
Roughly how long people report it takes to notice effects. A general guide from reports, not a promise, and not advice. Users report fast onset with potent but short-lived local effects, often noticed within hours to days of dosing.
First effects
Reported rapid localised fullness and blood-sugar sensations within days
Noticeable change
Reported subjective localised changes
Clear results
Reported cumulative anabolic effects over a short cycle
Commonly reported dosing & protocol
Reported figures only, NOT a recommendation or dosing advice. These are numbers people report using, compiled for education so you can make an informed decision. We do not advise anyone to take IGF-1 DES. Many peptides are not approved for human use in Australia. Speak to a qualified healthcare professional.
| Route | Subcutaneous injection, often localised near the targeted muscle |
|---|---|
| Typical reported dose | Reported community figures of roughly 30–100 mcg per dose |
| Frequency | Reported around training, e.g. pre or post-workout on training days |
| Cycle length | Reported in short runs, often a few weeks at a time |
Reported reconstitution (mg → units)
Illustration only: a 1 mg vial + 1 mL bacteriostatic water = 1 mg/mL. A 50 mcg (0.05 mg) dose is about 0.05 mL = 5 units on a U-100 insulin syringe.
Work out the units for your vial → CalculatorCommonly reported as daily dosing, sometimes peri-workout, over short blocks of a few weeks with breaks, framed as anecdotal reporting and not medical advice. Sold as a research reagent and not approved for human use in Australia.
Best used with / commonly stacked with
Combinations people report using together. Reported, not recommended, stacking can increase risks.
Safety notes
IGF-1 DES is not approved by the TGA for human use in Australia and is intended as a research reagent. Potent IGF-1 signalling carries theoretical risks including hypoglycaemia and effects on cell proliferation, and grey-market product purity cannot be verified by consumers. Anyone considering it should first consult a qualified healthcare professional.